RxDoctor Payments Data

Raj Desai, MD

Interventional Pain Medicine · West Hollywood, CANPI 1508258559

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,629 of the $8,392 with a category attached, or 79.0%. 17 manufacturers reported payments, led by Medtronic at 36.5% of the total. Reporting peaked in 2019 at $2,978 and has fallen 86.1% since, to $413 in 2025.

$8,392in general payments, 2019–2025

Across 113 payments — averaging $74.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$3K
  • Nevro Corp.$1K
  • Nalu Medical, Inc.$359
  • SPR Therapeutics, Inc$168
  • Pacira Pharmaceuticals Incorporated$155
  • plus $468 from 11 others

What the payments were for

  • Travel & lodging$1,76321%
  • Food & beverage$6,62979%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,392 in reported general payments places this provider in the 70th percentile of 188 interventional pain medicine providers in California.

See all interventional pain medicine providers in California

Medicare billing

Part B allowed, 2024
$525,089
Medicare patients
945
Services billed
4,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin394$3,139
Celecoxib57$1,611
Pregabalin100$1,165
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen77$1,046
Baclofen77$761
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen33$530
Methadone Hcl21$511
Acetaminophen-CodeineAcetaminophen With Codeine17$310
Duloxetine Hcl31$246
Diclofenac Sodium15$235
Tramadol Hcl21$208
Morphine Sulfate ErMorphine Sulfate11$199
Cyclobenzaprine Hcl14$104
Ibuprofen19$93
Diazepam19$7

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →